▲ Peaking
Health
🔮 fades
The end of Alzheimer’s?
New drug trials, fresh funding and a shift in clinical outlook are turning Alzheimer’s from untreatable to potentially preventable.
Drug Trials
8 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Drug Trials
This hub groups 8 separate news trends connected to Drug Trials, spanning June 30, 2026 through September 30, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 55 article observations and 49 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
Novartis Just Broke Out, Again, As Its Roche Rivalry Heats Up
Two positive Phase III results for an oral multiple sclerosis drug have pushed Novartis forward in a competitive pharmaceutical market.
◼ Archived
Business
🔮 fades ✓
Alnylam’s heart drug troubles take center stage at a cardiology conference
AstraZeneca's failed heart disease drug trial casts doubt on a promising class of treatments
◼ Archived
Health
New treatments for common cardiovascular risk factor near the market, with billions at stake
New cardiovascular treatments are poised to enter the market, with billions of dollars at stake.
◼ Archived
Health
🔮 fades ✓
Arthritis drug may help regrow up to 80% of hair in alopecia areata
A drug used to treat arthritis is showing promise in treating alopecia areata, a condition that causes hair loss.
◼ Archived
Business
Amylyx Stock Surges 55% After GLP-1 Blocker Hits All Trial Goals
Amylyx stock surged 55% after its GLP-1 blocker drug met all trial goals
◼ Archived
Business
🔮 fades ✓
Why Vertex Pharma Popped, As A Key Rival Plummeted 90%
Vertex Pharmaceuticals' stock surges as a rival's cystic fibrosis drug trial fails
◼ Archived
Business
🔮 fades ✓
EXCLUSIVE: US House committee opens investigation into Merck, AbbVie China drug trials
A US House committee has launched an investigation into Merck and AbbVie regarding drug trials conducted in China.